Full Spectrum Cannabis Hemp Oil with Cannabinoids: Treatment and Effects on Chronic Pain
The following information is presented for educational purposes only. Green Flower Botanicals, Inc. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by Green Flower Botanicals, Inc. and none should be inferred.
The opioid crisis is only now coming to a head across the United States and other industrialized nations around the world. It’s becoming increasingly clear that opioids do not hold the answers for chronic pain that medical professionals once believed they did.
While prescriptions, such as oxycontin, were once doled out without much forethought, doctors are now wondering what alternatives they have for treating chronic pain. Can non-psychoactive cannabinoids, like cannabidiol (CBD), hold the answer?
According to the research, cannabinoids hold exciting possibilities for people suffering from daily, and crippling pain. Not only is CBD completely natural, but it has so far been found to have little risk of side effects. Unlike its pharmaceutical counterparts, CBD has shown absolutely no risk for addiction and is well tolerated by all sectors of society.
Even a quick review of the literature, including the 19 recent studies on cannabinoids for the modulation of pain available here, is impressive. There is a building body of evidence that cannabinoids could be the key to safe chronic pain management in the future.
Chronic pain, although still a mystery in many senses, can be caused by inflammatory and neuropathic causes. Researchers believe that CBD and other cannabinoids can increase the function of a receptor called glycine receptors (GlyRs). These little-known receptors are responsible for one area of pain management.
According to an article published out of the National Institute of Health, even federally funded research is concluding that CBD could reduce pain associated with chronic inflammation and neuropathic pain. On top of this conclusion, they importantly mentioned that cannabinoids did not build up a tolerance, which is so common with other pain medications like opioids.
Nociceptive the term used to describe the way that the sensory nervous system responds to harmful external stimulation. In other words, it is one of the mechanisms that your body reacts to pain with. According to a team of researchers out of Italy, they discovered that both CBD and CBC interacted with this sensory nervous system. They concluded that, “These compounds might represent useful therapeutic agents with multiple mechanisms of action.”
Their results seemed to demonstrate that CBD and CBC, while both capable of reducing pain on their own, seemed to have a powerful synergistic effect. The research team also found that both these cannabinoids triggered activation of a healthy endocannabinoid system.
Interestingly, beyond its own therapeutic potential as a pain medication, CBD could actually boost the usefulness of other pain-killers. In a study published out of the University of Washington, researchers discovered that CBD could improve the pain regulation of another cannabinoid, THC.
The study, published in 2017, compared animal pain responses in lab rats. One group was given CBD only, while another was given THC injections followed later by CBD. It was uncovered that CBD prolonged the pain management of THC. It also seemed to increase the antinociceptive capability of THC, which means it boosted the capability of THC to block painful stimuli.
Research and Case Studies on the effects of Cannabis to treat Chronic Pain:
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
- Cannabis, pain, and sleep: Sativex Clinical Trials
- Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial
- Cannabinoids for neuropathic pain
- Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
- Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
- Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
- Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain
- Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
- Cannabinoids in the management of difficult to treat pain
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability ofTHC:CBD extract and THC extract in patients with intractable cancer-related pain
- Marijuana extract helps prevent chemo pain
- Pot users less likely to take painkillers
- CBD & THC interactions on acute pain and locomotor activity